Pharmaceutical Executive-11-01-2019

Pharrm Exec's 2020 Pipeline Report

Pharm Exec chronicles the journey of gene therapy visionary R. Jude Samulski, whose work unraveling the mysteries of adeno-associated virus continues to fuel new hopes in transforming drugs for rare disease.

Though uncertain market dynamics remain at play, the current magnitude of innovation in biopharma is staggering, and, at times, overwhelming.

Measure would cut drug costs, slash revenues, curb R&D.

A formal effort is underway in Europe to gather concrete clues on the value of real-world evidence in payer decision-making.

Technology grabbing the attention of watchful industry

With pursuits of complex therapies more routine, biotech platform companies are tasked with aligning their science with process and manufacturing proficiency to stand out in an increasingly crowded investment field.

Click the title above to open the Pharmaceutical Executive November 2019 issue in an interactive PDF format.

Boasting a long and proud tradition in the life sciences, consistently ranked among the world’s most pioneering countries, Sweden’s biggest task will be to maintain such standards in an era where medical science is becoming ever more sophisticated and integrated with other disciplines.